Trial Profile
A Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab, in Chinese Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) on a Background Therapy With Intranasal Corticosteroids
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary) ; Budesonide
- Indications Nasal congestion; Nasal polyps; Rhinosinusitis
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 09 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 29 May 2023 New trial record